| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mM * 1 mL in DMSO |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
在中性 pH 值下，原钒酸钠（钒酸盐）在浓度大于 0.1 mM 时也会开始聚合。经过几个小时的稀释后，十钒酸盐的黄橙色溶液可以转化为单体原钒酸钠（钒酸盐）的无色溶液。在氧化剂存在下，钒离子以原钒酸钠（钒酸盐：HVO42-或H2VO4-）的水合单体的形式存在，微摩尔浓度接近中性pH。在 pH 10 下沸腾可通过促进动力学上缓慢的解聚过程来加速该过程[1]。缺血引起的 ASK1 丝氨酸 83 和苏氨酸 845 的磷酸化状态可能会被原钒酸钠改变。脑缺血时，原钒酸钠可能会升高 PTEN 的酪氨酸磷酸化，并通过激活 Akt 进一步限制 ASK1 的激活[2]。
|
||
|---|---|---|---|
| 体内研究 (In Vivo) |
在心肌缺血性梗塞的大鼠模型中，原钒酸钠可挽救细胞免受缺血/再灌注损伤。原钒酸钠后治疗以剂量依赖性方式减少梗塞面积。原钒酸钠治疗还可改善再灌注 72 小时后左心室的收缩功能障碍。原钒酸钠处理的细胞保护作用与抑制胞质蛋白分解密切相关。原钒酸钠治疗可抑制缺血引起的 caspase-3 激活。
|
||
| 动物实验 |
|
||
| 药代性质 (ADME/PK) |
Metabolism / Metabolites
Vanadium is absorbed mainly via inhalation, though small amounts can be absorbed through the skin and gastrointestional tract. It is rapidly distributed in the plasma, mainly to the kidney, liver, lungs, heart, bone, where it tends to accumulate. With the help of cytochrome P-450 enzymes, it can interconvert between its two oxidation states, vanadyl (V+4) and vanadate (V+5). Both states of vanadium can reversibly bind to transferrin protein in the blood and then be taken up into erythrocytes. Vanadium is excreted mainly in the urine. (L837) |
||
| 毒性/毒理 (Toxicokinetics/TK) |
Toxicity Summary
Vanadium damages alveolar macrophages by decreasing the macrophage membrane integrity, thus impairing the cells' phagocytotic ability and viability. The pentavalent form of vanadium, vanadate, is a potent inhibitor of the Ca+-ATPase and Na+,K+-ATPase of plasma membranes, which decreases intracellular ATP concentration. Vanadium is also believed to induce the production of reactive oxygen species. This may damage DNA and also cause oxidative stress, which can damage the reproductive system. Vanadium also inhibits protein tyrosine phosphatases, producing insulin-like effects. (L837, A247, A248, A249, A250, A251) |
||
| 参考文献 | |||
| 其他信息 |
Trisodium vanadate is an inorganic sodium salt of formula Na3VO4 containing the tetrahedral VO4(3-) It has a role as an EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor, a radiation protective agent, an apoptosis inducer and an antineoplastic agent. It contains a vanadate(3-).
Sodium orthovanadate is a chemical compound of sodium and vanadium. It is often added to buffer solutions that are used in protein analysis in molecular biology. The aim is to preserve the phosphorylation of proteins of interest by inhibiting endogenous phosphatases present in cell lysate mixture. Vanadium is a transition metal with the chemical symbol V and atomic number 23. The element usually combines with other elements such as oxygen, sodium, sulfur, or chloride, and occurs naturally in about 65 different minerals and in fossil fuel deposits. Vanadium is found in many organisms, and is used by some life forms as an active center of enzymes. (L837, L838, L854) Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects. |
| 分子式 |
NA3O4V
|
|
|---|---|---|
| 分子量 |
183.91
|
|
| 精确质量 |
183.892
|
|
| CAS号 |
13721-39-6
|
|
| 相关CAS号 |
|
|
| PubChem CID |
61671
|
|
| 外观&性状 |
Off-white to light yellow solid powder
|
|
| 熔点 |
850-866 °C(lit.)
|
|
| tPSA |
86.25
|
|
| 氢键供体(HBD)数目 |
0
|
|
| 氢键受体(HBA)数目 |
4
|
|
| 可旋转键数目(RBC) |
0
|
|
| 重原子数目 |
8
|
|
| 分子复杂度/Complexity |
36.8
|
|
| 定义原子立体中心数目 |
0
|
|
| InChi Key |
IHIXIJGXTJIKRB-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/3Na.4O.V/q3*+1;;3*-1;
|
|
| 化学名 |
trisodium;trioxido(oxo)vanadium
|
|
| 别名 |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。 |
|
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
H2O : ~8.33 mg/mL (~45.29 mM)
DMSO :< 1 mg/mL |
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: 16.67 mg/mL (90.64 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。 (<60°C).
配方 2 中的溶解度: Saline:30mg/mL 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4374 mL | 27.1872 mL | 54.3744 mL | |
| 5 mM | 1.0875 mL | 5.4374 mL | 10.8749 mL | |
| 10 mM | 0.5437 mL | 2.7187 mL | 5.4374 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
JCS-1
PDE1-IN-6
N-Lauryldiethanolamine
DPM-1003
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
粤公网安备 44011102003439号